Document Detail


Value of N-terminal brain natriuretic peptide as a prognostic marker in patients with CKD: results from the CREATE study.
MedLine Citation:
PMID:  20849244     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
BACKGROUND AND OBJECTIVES: This study assessed plasma N-terminal prohormone brain natriuretic peptide (NT-proBNP) as a prognostic marker of cardiovascular risk in patients with chronic kidney disease stages 3-4 and anaemia treated with epoetin beta to two haemoglobin target ranges.
DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: Of 603 patients enrolled in the Cardiovascular Risk Reduction by Early Anaemia Treatment with Epoetin Beta (CREATE) trial (baseline creatinine clearance 15-35 mL/min; haemoglobin 11.0-12.5 g/dL), 291 were included in this sub-study. Patients received subcutaneous epoetin beta either immediately after randomisation (target 13.0-15.0 g/dL; Group 1), or after their haemoglobin levels had fallen < 10.5 g/dL (target 10.5-11.5 g/dL; Group 2). Chronic heart failure New York Heart Association class III-IV was an exclusion criterion. (ClinicalTrials.gov Identifier: NCT00321919)
RESULTS: Cardiovascular event rates were higher in patients with baseline NT-proBNP > 400 vs. ≤ 400 pg/mL (39 vs. 13 events; p = 0.0002). Dialysis was initiated in 68 vs. 42 patients with NT-proBNP > 400 vs. ≤ 400 pg/mL (p = 0.0003). Amongst patients with NT-proBNP > 400 pg/mL, there was no significant difference between treatment groups in risk of cardiovascular events (HR = 0.57; p = 0.08) or time to dialysis (HR = 0.65; p = 0.08). The overall interpretation of this substudy is, however, limited by its relatively small sample size which, together with low clinical event rates, result in a lack of statistical power for some analyses and should be viewed as being hypothesis-generating in nature.
CONCLUSIONS: In chronic kidney disease patients with mild-to-moderate anaemia, elevated baseline plasma NT-proBNP levels are associated with a higher risk of cardiovascular events and an accelerated progression towards end-stage renal disease.
Authors:
Francesco Locatelli; Kai-Uwe Eckardt; Iain C Macdougall; Dimitrios Tsakiris; Naomi Clyne; Hans-Ulrich Burger; Armin Scherhag; Tilman B Drüeke;
Related Documents :
2981594 - Fibronectin plasma levels after cadaver kidney transplantation.
16970264 - Prevalence and pattern of renal osteodystrophy in chronic hemodialysis patients: a cros...
11956114 - Multimarker approach to risk stratification in non-st elevation acute coronary syndrome...
15921794 - Incidence of normal values of natriuretic peptides in patients with chronic heart failu...
16599054 - Use of complementary and alternative medicine among patients attending rheumatology cli...
21239404 - Prognostic electrocardiographic parameters in patients with suspected myocarditis.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-09-17
Journal Detail:
Title:  Current medical research and opinion     Volume:  26     ISSN:  1473-4877     ISO Abbreviation:  Curr Med Res Opin     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0351014     Medline TA:  Curr Med Res Opin     Country:  England    
Other Details:
Languages:  eng     Pagination:  2543-52     Citation Subset:  IM    
Affiliation:
Dialysis and Renal Transplantation, Ospedale A. Manzoni, Lecco, Italy. nephrologia@ospedale.lecco.it
Data Bank Information
Bank Name/Acc. No.:
ClinicalTrials.gov/NCT00321919
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment.
Next Document:  Towards objective evaluation of perceived roughness and breathiness: An approach based on mel-freque...